Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Despite advances in treatment, the prognosis remains poor, highlighting the need for novel therapeutic strategies. The present review explores the potential of targeted epidermal growth factor receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Crintea, Andreea, Constantin, Anne-Marie, Motofelea, Alexandru C., Crivii, Carmen-Bianca, Velescu, Maria A., Coșeriu, Răzvan L., Ilyés, Tamás, Crăciun, Alexandra M., Silaghi, Ciprian N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10532491/
https://www.ncbi.nlm.nih.gov/pubmed/37754880
http://dx.doi.org/10.3390/jfb14090466
Descripción
Sumario:Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide. Despite advances in treatment, the prognosis remains poor, highlighting the need for novel therapeutic strategies. The present review explores the potential of targeted epidermal growth factor receptor (EGFR) nanotherapy as an alternative treatment for NSCLC, showing that EGFR-targeted nanoparticles are efficiently taken up by NSCLC cells, leading to a significant reduction in tumor growth in mouse models. Consequently, we suggest that targeted EGFR nanotherapy could be an innovative treatment strategy for NSCLC; however, further studies are needed to optimize the nanoparticles and evaluate their safety and efficacy in clinical settings and human trials.

Ejemplares similares